Your browser doesn't support javascript.
loading
Gilbert's syndrome revisited.
Vítek, Libor; Tiribelli, Claudio.
Affiliation
  • Vítek L; 1st Faculty of Medicine, Charles University and General University Hospital in Prague, Prague, Czech Republic. Electronic address: vitek@cesnet.cz.
  • Tiribelli C; Fondazione Italiana Fegato, Trieste, Italy. Electronic address: ctliver@fegato.it.
J Hepatol ; 79(4): 1049-1055, 2023 10.
Article in En | MEDLINE | ID: mdl-37390966
ABSTRACT
Gilbert's syndrome, also known as benign hyperbilirubinaemia, was described more than 100 years ago. It has usually been considered a physiological abnormality characterised by a mild elevation of the systemic level of unconjugated bilirubin, in the absence of any underlying liver or overt haemolytic disease. However, since the re-discovery of the potent antioxidant effects of bilirubin in the late 1980s, as well as multiple intracellular signalling pathways affected by bilirubin, an ever-increasing body of evidence suggests that individuals with Gilbert's syndrome may benefit from the mild hyperbilirubinaemia and are actually protected from the development of a wide variety of "diseases of civilisation" such as cardiovascular diseases, certain cancers, and autoimmune or neurodegenerative diseases. This review analyses the current state of medical knowledge given recent discoveries in this rapidly developing field, as well as their possible clinical significance, and provides a new perspective on this condition.
Subject(s)
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Gilbert Disease Limits: Humans Language: En Journal: J Hepatol Journal subject: GASTROENTEROLOGIA Year: 2023 Document type: Article

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Gilbert Disease Limits: Humans Language: En Journal: J Hepatol Journal subject: GASTROENTEROLOGIA Year: 2023 Document type: Article